

# Tatsuo Kanda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3187391/publications.pdf>

Version: 2024-02-01

253  
papers

5,807  
citations

101496

36  
h-index

118793

62  
g-index

257  
all docs

257  
docs citations

257  
times ranked

6854  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. <i>Hepatology</i> , 2003, 37, 19-26.	3.6	362
2	APASL consensus statements and recommendation on treatment of hepatitis C. <i>Hepatology International</i> , 2016, 10, 702-726.	1.9	189
3	Apoptosis and non-alcoholic fatty liver diseases. <i>World Journal of Gastroenterology</i> , 2018, 24, 2661-2672.	1.4	189
4	Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1358.	1.8	184
5	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	1.9	152
6	Bezafibrate treatment: a new medical approach for PBC patients?. <i>Journal of Gastroenterology</i> , 2003, 38, 573-578.	2.3	121
7	Hepatitis C virus NS5A inhibitors and drug resistance mutations. <i>World Journal of Gastroenterology</i> , 2014, 20, 2902.	1.4	116
8	New antiviral therapies for chronic hepatitis C. <i>Hepatology International</i> , 2010, 4, 548-561.	1.9	99
9	Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1406.	1.8	91
10	Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. <i>Liver International</i> , 2008, 28, 355-362.	1.9	90
11	Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes. <i>Journal of Virology</i> , 2006, 80, 4633-4639.	1.5	84
12	Efficacy and safety of sofosbuvir+velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. <i>Journal of Gastroenterology</i> , 2019, 54, 87-95.	2.3	83
13	Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect. <i>Journal of Virology</i> , 2007, 81, 669-676.	1.5	80
14	Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling. <i>Journal of Virology</i> , 2008, 82, 11066-11072.	1.5	76
15	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016, 10, 681-701.	1.9	75
16	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019, 13, 649-661.	1.9	72
17	The role of TT virus infection in acute viral hepatitis. <i>Hepatology</i> , 1999, 29, 1905-1908.	3.6	66
18	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1525.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Fulminant hepatic failure associated with benzbromarone treatment: A case report. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 625-626.	1.4	64
20	Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells. <i>Journal of Virology</i> , 2007, 81, 3933-3941.	1.5	64
21	Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 12989.	1.4	58
22	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 38-51.	4.2	58
23	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. <i>Investigational New Drugs</i> , 2020, 38, 172-180.	1.2	57
24	Silencing of Hepatitis A Virus Infection by Small Interfering RNAs. <i>Journal of Virology</i> , 2006, 80, 5599-5610.	1.5	55
25	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 382-396.	4.2	54
26	Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. <i>Journal of Hepatology</i> , 2010, 52, 72-78.	1.8	53
27	Key HLA-DRB1*07:01 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. <i>Hepatology</i> , 2018, 68, 848-858.	3.6	53
28	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52
29	Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. <i>World Journal of Gastroenterology</i> , 2014, 20, 9229-36.	1.4	51
30	Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes. <i>Journal of Virology</i> , 2007, 81, 12375-12381.	1.5	46
31	Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. <i>Human Molecular Genetics</i> , 2017, 26, dww406.	1.4	46
32	Hepatitis C Virus Infection Impairs IRF-7 Translocation and Alpha Interferon Synthesis in Immortalized Human Hepatocytes. <i>Journal of Virology</i> , 2010, 84, 10991-10998.	1.5	44
33	Hepatitis C Virus Nonstructural 5A Protein Inhibits Lipopolysaccharide-Mediated Apoptosis of Hepatocytes by Decreasing Expression of Toll-Like Receptor 4. <i>Journal of Infectious Diseases</i> , 2011, 204, 793-801.	1.9	43
34	Current management of patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1913.	0.8	40
35	The androgen receptor as an emerging target in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 91.	1.8	39
36	Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21455-21467.	1.8	38

#	ARTICLE	IF	CITATIONS
37	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 7958.	1.6	38
38	Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0174153.	1.1	38
39	MicroRNA-122 Inhibits the Production of Inflammatory Cytokines by Targeting the PKR Activator PACT in Human Hepatic Stellate Cells. <i>PLoS ONE</i> , 2015, 10, e0144295.	1.1	37
40	Interference of hepatitis A virus replication by small interfering RNAs. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 341-345.	1.0	36
41	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204.	1.4	36
42	Inhibition of Intrahepatic Gamma Interferon Production by Hepatitis C Virus Nonstructural Protein 5A in Transgenic Mice. <i>Journal of Virology</i> , 2009, 83, 8463-8469.	1.5	35
43	Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 955-961.	0.6	35
44	Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. <i>Experimental Cell Research</i> , 2014, 323, 326-336.	1.2	35
45	Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. <i>World Journal of Gastroenterology</i> , 2014, 20, 7197.	1.4	35
46	Downregulation of microRNA-431 by human interferon- $\gamma$ inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. <i>International Journal of Oncology</i> , 2014, 44, 1685-1690.	1.4	34
47	Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. <i>World Journal of Gastroenterology</i> , 2013, 19, 8940.	1.4	33
48	Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. <i>Biochemical and Biophysical Research Communications</i> , 2005, 330, 1217-1223.	1.0	32
49	Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 621-629.	1.0	32
50	Hepatitis B Virus e Antigen Downregulates Cytokine Production in Human Hepatoma Cell Lines. <i>Viral Immunology</i> , 2010, 23, 467-476.	0.6	32
51	Hepatitis B Virus e Antigen Physically Associates With Receptor-Interacting Serine/Threonine Protein Kinase 2 and Regulates IL-6 Gene Expression. <i>Journal of Infectious Diseases</i> , 2012, 206, 415-420.	1.9	32
52	No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. <i>PLoS ONE</i> , 2013, 8, e81312.	1.1	30
53	The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 908-912.	1.0	30
54	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. <i>Hepatology International</i> , 2015, 9, 424-430.	1.9	30

#	ARTICLE	IF	CITATIONS
55	Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region. <i>PLoS ONE</i> , 2013, 8, e73615.	1.1	29
56	N-Nitroso-Fenfluramine Hepatotoxicity Resembling Chronic Hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 999-1000.	1.4	28
57	Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. <i>Virology Journal</i> , 2010, 7, 212.	1.4	28
58	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 906.	1.8	28
59	Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. <i>PLoS ONE</i> , 2017, 12, e0177302.	1.1	28
60	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 1088.	1.1	28
61	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 473-484.	4.2	28
62	Hepatitis A outbreak associated with a revolving sushi bar in Chiba, Japan: Application of molecular epidemiology. <i>Hepatology Research</i> , 2012, 42, 828-834.	1.8	27
63	Treatment of hepatitis C virus infection in the future. <i>Clinical and Translational Medicine</i> , 2013, 2, 9.	1.7	27
64	Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. <i>International Journal of Medical Sciences</i> , 2016, 13, 418-423.	1.1	27
65	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. <i>Hepatology International</i> , 2019, 13, 103-109.	1.9	26
66	Current and future directions for treating hepatitis B virus infection. <i>World Journal of Hepatology</i> , 2015, 7, 1541.	0.8	26
67	5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. <i>Oncology Reports</i> , 2005, 14, 975-9.	1.2	26
68	Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3335-3342.	1.1	25
69	The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 567-571.	1.0	25
70	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
71	Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2011, 6, e28617.	1.1	24
72	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. <i>Hepatology International</i> , 2018, 12, 523-530.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. <i>World Journal of Hepatology</i> , 2015, 7, 1133.	0.8	24
74	Emergence of entecavir-resistant mutations in nucleos(t)ide-naïve Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1111-1117.	0.6	23
75	Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin. <i>Viruses</i> , 2012, 4, 1264-1278.	1.5	23
76	POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. <i>Scientific Reports</i> , 2019, 9, 102.	1.6	23
77	Hepatitis C Virus and Hepatocellular Carcinoma. <i>Biology</i> , 2013, 2, 304-316.	1.3	22
78	Factors associated with the effect of interferon- $\alpha$ sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2015, 45, 1195-1202.	1.8	22
79	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 707-712.	1.1	21
80	Two-dimensional shear wave elastography with propagation-based reliability assessment for grading hepatic fibrosis and portal hypertension. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 595-602.	1.4	21
81	Suppression of La Antigen Exerts Potential Antiviral Effects against Hepatitis A Virus. <i>PLoS ONE</i> , 2014, 9, e101993.	1.1	21
82	Fulminant hepatic failure associated with triazolam. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1111-1114.	1.1	20
83	SEVERE HEPATOTOXICITY ASSOCIATED WITH CHINESE DIET PRODUCT 'ONSHIDOU-GENBI-KOUNOU'. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 354-355.	1.4	20
84	Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. <i>Hepatology Research</i> , 2012, 42, 248-253.	1.8	20
85	Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3305-3308.	0.8	20
86	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. <i>International Journal of Medical Sciences</i> , 2018, 15, 466-474.	1.1	20
87	Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3349.	1.8	20
88	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	1.6	20
89	Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 1-6.	0.7	20
90	Enhanced Sensitivity of Human Hepatoma Cells to 5-Fluorouracil by Small Interfering RNA Targeting Bcl-2. <i>DNA and Cell Biology</i> , 2005, 24, 805-809.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Analysis of 5' Nontranslated Region of Hepatitis A Viral RNA Genotype I from South Korea: Comparison with Disease Severities. PLoS ONE, 2010, 5, e15139.	1.1	19
92	Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells. PLoS ONE, 2016, 11, e0146314.	1.1	19
93	Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression. International Journal of Medical Sciences, 2018, 15, 1153-1159.	1.1	19
94	Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients. Journal of Medical Virology, 2019, 91, 411-418.	2.5	19
95	Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. International Journal of Molecular Sciences, 2020, 21, 4906.	1.8	19
96	Analysis of HBV Genomes Integrated into the Genomes of Human Hepatoma PLC/PRF/5 Cells by HBV Sequence Capture-Based Next-Generation Sequencing. Genes, 2020, 11, 661.	1.0	19
97	Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. Journal of Clinical and Translational Hepatology, 2015, 3, 205-210.	0.7	19
98	Interleukin-29 Suppresses Hepatitis A and C Viral Internal Ribosomal Entry Site-Mediated Translation. Viral Immunology, 2012, 25, 379-386.	0.6	18
99	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatology International, 2015, 9, 486-507.	1.9	18
100	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatology International, 2016, 10, 574-593.	1.9	18
101	Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma. Cancers, 2017, 9, 43.	1.7	18
102	Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection. Viruses, 2020, 12, 533.	1.5	18
103	New treatments for genotype 1 chronic hepatitis C &ndash; focus on simeprevir. Therapeutics and Clinical Risk Management, 2014, 10, 387.	0.9	17
104	EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Scientific Reports, 2021, 11, 21396.	1.6	17
105	Faldaprevir for the Treatment of Hepatitis C. International Journal of Molecular Sciences, 2015, 16, 4985-4996.	1.8	16
106	Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 212-219.	1.4	16
107	Cooperative effects of hepatitis B virus and TNF may play important roles in the activation of metabolic pathways through the activation of NF- $\kappa$ B. International Journal of Molecular Medicine, 2016, 38, 475-481.	1.8	16
108	Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatology International, 2017, 11, 38-44.	1.9	16

#	ARTICLE	IF	CITATIONS
109	Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 872-877.	0.6	15
110	Internal ribosomal entry site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine. <i>Hepatology Research</i> , 2010, 40, 415-423.	1.8	15
111	Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients. <i>Oncology</i> , 2011, 80, 366-372.	0.9	15
112	Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan. <i>Hepatology Research</i> , 2012, 42, 974-981.	1.8	15
113	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	2.3	15
114	Sofosbuvir treatment and hepatitis C virus infection. <i>World Journal of Hepatology</i> , 2016, 8, 183.	0.8	15
115	Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. <i>Cancer Science</i> , 2007, 98, 1921-1929.	1.7	14
116	Hepatitis C Virus Nonstructural Protein 5A Inhibits Thapsigargin-Induced Apoptosis. <i>PLoS ONE</i> , 2014, 9, e113499.	1.1	14
117	MBP-1 Inhibits Breast Cancer Growth and Metastasis in Immunocompetent Mice. <i>Cancer Research</i> , 2009, 69, 9354-9359.	0.4	13
118	Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines. <i>Immunology Letters</i> , 2013, 152, 8-15.	1.1	13
119	Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress. <i>Oncology Reports</i> , 2014, 32, 2343-2348.	1.2	13
120	A semi-supervised tensor regression model for siRNA efficacy prediction. <i>BMC Bioinformatics</i> , 2015, 16, 80.	1.2	13
121	Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure: analysis in a Japanese center. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 756-762.	1.4	13
122	Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2020, 40, 4445-4455.	0.5	13
123	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 549, 171-178.	1.0	13
124	Prolonged acute hepatitis A mimicking autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2005, 11, 3791.	1.4	13
125	5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. <i>Oncology Reports</i> , 2005, 14, 975.	1.2	12
126	Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells. <i>Cytokine</i> , 2013, 64, 577-583.	1.4	12



#	ARTICLE	IF	CITATIONS
127	Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 1192-1195.	1.0	12
128	Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 694-699.	1.0	12
129	Antiviral activity of zinc sulfate against hepatitis A virus replication. <i>Future Virology</i> , 2019, 14, 399-406.	0.9	12
130	Additive Effects of Zinc Chloride on the Suppression of Hepatitis A Virus Replication by Interferon in Human Hepatoma Huh7 Cells. <i>In Vivo</i> , 2020, 34, 3301-3308.	0.6	12
131	Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2631.	1.8	12
132	Platelet count and sustained virological response in hepatitis C treatment. <i>World Journal of Hepatology</i> , 2013, 5, 182.	0.8	11
133	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. <i>International Journal of Medical Sciences</i> , 2016, 13, 310-315.	1.1	11
134	Autoimmune hepatitis following drug-induced liver injury in an elderly patient. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 156-159.	0.4	11
135	Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. <i>Biology</i> , 2017, 6, 30.	1.3	11
136	Early Combination Therapy with Corticosteroid and Nucleoside Analogue Induces Rapid Resolution of Inflammation in Acute Liver Failure due to Transient Hepatitis B Virus Infection. <i>Internal Medicine</i> , 2018, 57, 1543-1552.	0.3	11
137	Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. <i>World Journal of Hepatology</i> , 2015, 7, 1125.	0.8	11
138	Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients. <i>International Journal of Medical Sciences</i> , 2013, 10, 647-652.	1.1	10
139	HBV Core Protein Enhances Cytokine Production. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 213-220.	1.0	10
140	The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2017, 52, 113-122.	2.3	10
141	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
142	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. <i>Oncotarget</i> , 2018, 9, 11631-11637.	0.8	10
143	Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. <i>Oncotarget</i> , 2018, 9, 26183-26194.	0.8	10
144	Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. <i>World Journal of Gastroenterology</i> , 2017, 23, 5645.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. <i>Hepato-Gastroenterology</i> , 2005, 52, 1233-5.	0.5	10
146	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2549.	1.7	10
147	Occurrence of Autoimmune Hepatitis During the Course of Primary Biliary Cirrhosis: Report of Two Cases. <i>Digestive Diseases and Sciences</i> , 2006, 51, 45-46.	1.1	9
148	Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. <i>International Journal of Medical Sciences</i> , 2013, 10, 1015-1021.	1.1	9
149	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. <i>International Journal of Hepatology</i> , 2014, 2014, 1-6.	0.4	9
150	Importance of the poor prognosis of severe and fulminant hepatitis in the elderly in an era of a highly aging society: Analysis in a Japanese center. <i>Hepatology Research</i> , 2015, 45, 863-871.	1.8	9
151	Reappearance of serum hepatitis B viral DNA in patients with hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2015, 62, 1329-1329.	3.6	9
152	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Oncology</i> , 2016, 90, 199-208.	0.9	9
153	Interferon induces interleukin 8 and bone marrow stromal cell antigen 2 expression, inhibiting the production of hepatitis B virus surface antigen from human hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 858-863.	1.0	9
154	Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. <i>Hepatology International</i> , 2018, 12, 90-93.	1.9	9
155	Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus. <i>International Journal of Medical Sciences</i> , 2019, 16, 1366-1370.	1.1	9
156	Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6384.	1.8	9
157	Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B. <i>International Journal of Medical Sciences</i> , 2012, 9, 27-32.	1.1	9
158	Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. <i>Cell Death and Disease</i> , 2021, 12, 1073.	2.7	9
159	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. <i>Hepatology International</i> , 2013, 7, 144-152.	1.9	8
160	Ultra-Deep Sequencing Analysis of the Hepatitis A Virus 5'-Untranslated Region among Cases of the Same Outbreak from a Single Source. <i>International Journal of Medical Sciences</i> , 2014, 11, 60-64.	1.1	8
161	Opportunistic infection in patients with acute liver failure. <i>Hepatology International</i> , 2014, 8, 233-239.	1.9	8
162	Recent Trend of Hepatitis E Virus Infection in Chiba Area, Japan: 3 of 5 Cases with Rheumatoid Arthritis. <i>Case Reports in Gastroenterology</i> , 2015, 9, 317-326.	0.3	8

#	ARTICLE	IF	CITATIONS
163	Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. <i>Case Reports in Gastroenterology</i> , 2016, 10, 366-372.	0.3	8
164	Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism. <i>Oncology Letters</i> , 2017, 13, 4481-4486.	0.8	8
165	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 977-989.	2.3	8
166	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2021, 12, 2694-2701.	1.2	8
167	Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7420.	1.8	8
168	Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection. <i>Surgery</i> , 2021, 170, 167-172.	1.0	8
169	Application of artificial intelligence in hepatology: Minireview. <i>Artificial Intelligence in Gastroenterology</i> , 2020, 1, 5-11.	0.2	8
170	Hepatitis C virus genotypes in Myanmar. <i>World Journal of Gastroenterology</i> , 2016, 22, 6095.	1.4	8
171	Acute hepatitis C virus infection, 1986-2001: a rare cause of fulminant hepatitis in Chiba, Japan. <i>Hepato-Gastroenterology</i> , 2004, 51, 556-8.	0.5	8
172	Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. <i>BMC Gastroenterology</i> , 2016, 16, 66.	0.8	7
173	Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease. <i>International Journal of Medical Sciences</i> , 2019, 16, 909-921.	1.1	7
174	Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. <i>World Journal of Hepatology</i> , 2018, 10, 898-906.	0.8	7
175	High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis. <i>BioScience Trends</i> , 2020, 14, 368-375.	1.1	7
176	Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 205.	0.8	7
177	Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. <i>Journal of Medical Virology</i> , 2007, 79, 683-693.	2.5	6
178	Determination of serum carbohydrate-deficient transferrin by a nephelometric immunoassay for differential diagnosis of alcoholic and non-alcoholic liver diseases. <i>Clinica Chimica Acta</i> , 2018, 485, 181-186.	0.5	6
179	Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. <i>Hepatology International</i> , 2018, 12, 291-293.	1.9	6
180	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. <i>World Journal of Gastroenterology</i> , 2017, 23, 8120-8127.	1.4	6

#	ARTICLE	IF	CITATIONS
181	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6
182	Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients. <i>Chinese Medical Journal</i> , 2013, 126, 4568-74.	0.9	6
183	Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6044.	1.8	6
184	Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation. <i>Case Reports in Gastroenterology</i> , 2016, 10, 248-256.	0.3	5
185	Hepatitis A virus genotype IA-infected patient with marked elevation of aspartate aminotransferase levels. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 52-56.	0.4	5
186	Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC. <i>Anticancer Research</i> , 2019, 39, 3855-3862.	0.5	5
187	Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 147.	0.8	5
188	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. <i>International Journal of Medical Sciences</i> , 2020, 17, 874-880.	1.1	5
189	Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan. <i>Viruses</i> , 2021, 13, 207.	1.5	5
190	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. <i>Scientific Reports</i> , 2021, 11, 3703.	1.6	5
191	Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 761.	0.8	5
192	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. <i>Oncotarget</i> , 2018, 9, 5509-5513.	0.8	5
193	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. <i>Oncotarget</i> , 2018, 9, 16263-16270.	0.8	5
194	Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman. <i>World Journal of Gastroenterology</i> , 2004, 10, 2607.	1.4	5
195	Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series. <i>Anticancer Research</i> , 2021, 41, 6225-6230.	0.5	5
196	Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy. <i>European Journal of Pediatrics</i> , 2005, 164, 212-215.	1.3	4
197	Opportunistic infection in the patients with acute liver failure: a report of three cases with one fatality. <i>Clinical Journal of Gastroenterology</i> , 2009, 2, 420-424.	0.4	4
198	Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy. <i>International Journal of Medical Sciences</i> , 2013, 10, 43-49.	1.1	4

#	ARTICLE	IF	CITATIONS
199	Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF- $\kappa$ B-Nuclear Translocation. PLoS ONE, 2015, 10, e0131973.	1.1	4
200	Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon $\alpha$ -2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype. Case Reports in Gastroenterology, 2015, 9, 215-220.	0.3	4
201	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases. Diseases (Basel, Switzerland), 2016, 4, 38.	1.0	4
202	Successful Management of Acute Liver Failure Patients Waiting for Liver Transplantation by On-Line Hemodiafiltration with an Arteriovenous Fistula. Case Reports in Gastroenterology, 2016, 10, 144-150.	0.3	4
203	Quantitative Ultrasound Image Analysis Helps in the Differentiation of Hepatocellular Carcinoma ( ) Tj ETQq1 1 0.784314 rgBT /Overlook Invasion. Journal of Ultrasound in Medicine, 2021, 40, 689-698.	0.8	4
204	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World Journal of Virology, 2015, 4, 178.	1.3	4
205	Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. Journal of Clinical Medicine, 2021, 10, 5529.	1.0	4
206	The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 7878.	1.8	4
207	Hepatitis A protein VP1-2A reduced cell viability in Huh-7 cells with hepatitis C virus subgenomic RNA replication. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 625-626.	1.4	3
208	Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clinical Journal of Gastroenterology, 2013, 6, 160-163.	0.4	3
209	Acute Liver Injury in a Patient with Alcohol Dependence: A Case Resembling Autoimmune Hepatitis or Drug-Induced Liver Injury. Case Reports in Gastroenterology, 2014, 8, 129-133.	0.3	3
210	Role of IL28B genotype in older hepatitis C virus-infected patients. World Journal of Immunology, 2013, 3, 54.	0.5	3
211	Body mass index in Japanese patients with autoimmune liver disease: overweight patients with primary biliary cirrhosis tend to be asymptomatic. Hepato-Gastroenterology, 2007, 54, 1758-60.	0.5	3
212	Acute Liver Failure in an Antimitochondrial Antibody-Positive 63-Year-Old Man. Case Reports in Gastroenterology, 2012, 6, 394-399.	0.3	2
213	Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients. Case Reports in Oncology, 2014, 7, 288-296.	0.3	2
214	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. Acta Hepatologica Japonica, 2017, 58, 647-653.	0.0	2
215	Hepatitis B Virus Genotype C is Predominant in Myanmar. Diseases (Basel, Switzerland), 2018, 6, 3.	1.0	2
216	Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma. Hepatology International, 2019, 13, 519-520.	1.9	2

#	ARTICLE	IF	CITATIONS
217	Long-term follow-up of a Japanese patient with hepatitis B virus genotype H and human immunodeficiency virus coinfection. <i>Future Virology</i> , 2019, 14, 633-639.	0.9	2
218	Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer. <i>JGH Open</i> , 2021, 5, 722-724.	0.7	2
219	Ultrasonographic grayscale findings related to fibrosis in patients with non-alcoholic fatty liver disease: comparison with transient elastography and Fib-4 index. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 323-333.	0.6	2
220	IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. <i>World Journal of Hepatology</i> , 2013, 5, 635.	0.8	2
221	Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan?. <i>Hepato-Gastroenterology</i> , 2005, 52, 180-2.	0.5	2
222	Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 425-432.	0.6	2
223	Hepatitis A Virus Infection and Molecular Research. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7214.	1.8	2
224	Sequence-motif analysis of 5' untranslated region of GB virus in Japanese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1048-1053.	1.4	1
225	Acute Liver Failure Occurring during the First Trimester of Pregnancy Successfully Treated with Living Donor Liver Transplantation. <i>Case Reports in Transplantation</i> , 2013, 2013, 1-4.	0.1	1
226	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis. <i>International Medical Case Reports Journal</i> , 2014, 7, 103.	0.3	1
227	Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21177-21190.	1.8	1
228	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2017, 58, 605-610.	0.0	1
229	Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences. <i>International Journal of Molecular Sciences</i> , 2017, 18, 172.	1.8	1
230	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. <i>Acta Hepatologica Japonica</i> , 2021, 62, 25-32.	0.0	1
231	HCV GT1b-patient with alanine aminotransferase elevation and sustained virologic response achieved by grazoprevir/elbasvir discontinuation. <i>Future Virology</i> , 2021, 16, 161-165.	0.9	1
232	Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. <i>Internal Medicine</i> , 2021, 60, 2061-2066.	0.3	1
233	Androgen Receptor and Hepatocellular Carcinoma. , 2013, 01, .		1
234	Successful Treatment of a Pregnant Woman with Chronic Active Hepatitis B using Tenofovir Disoproxil Fumarate. <i>OBM Hepatology and Gastroenterology</i> , 2017, 01, 1-1.	0.0	1

#	ARTICLE	IF	CITATIONS
235	The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection. <i>Viruses</i> , 2021, 13, 2216.	1.5	1
236	Inhibition of subgenomic hepatitis C virus RNA replication in HeLa cells. <i>Hepato-Gastroenterology</i> , 2007, 54, 32-5.	0.5	1
237	<i>Internal Medicine</i> , 2015, 104, 1861-1865.	0.0	0
238	Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. <i>International Journal of Medical Sciences</i> , 2017, 14, 1088-1093.	1.1	0
239	Drug-Induced Liver Injury Associated with Complementary and Alternative Medicines. <i>Case Reports in Gastroenterology</i> , 2017, 10, 706-713.	0.3	0
240	Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 423-425.	0.7	0
241	Analysis of full-length hepatitis B virus genome from chronic hepatitis B-patients with higher alanine aminotransferase elevation. <i>Future Virology</i> , 2020, 15, 429-439.	0.9	0
242	Artificial intelligence and machine learning could support drug development for hepatitis A virus internal ribosomal entry sites. <i>Artificial Intelligence in Gastroenterology</i> , 2021, 2, 1-9.	0.2	0
243	No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 579-581.	1.9	0
244	Large-volume cell-free and concentrated ascites reinfusion therapy improves venous flow in patients with liver cirrhosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 315-322.	0.6	0
245	A case of Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 548-554.	0.0	0
246	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 656-662.	0.0	0
247	Pneumocystis jirovecii pneumonia Suspected Due to Low-Dosage Prednisolone Treatment for Acute Autoimmune Hepatitis: Case Report and Literature Review. , 2017, 1, .		0
248	Response-Guided Treatment with an Ultrarapid Virological Response Creates the Future of Interferon-Free Treatment against Hepatitis C. , 2017, 1, .		0
249	Interferon-Free Treatment for Chronic Hepatitis C in Japan. <i>Journal of the Nihon University Medical Association</i> , 2018, 77, 123-125.	0.0	0
250	Nutritional Treatment of Liver Disease. <i>Journal of the Nihon University Medical Association</i> , 2019, 78, 231-236.	0.0	0
251	Successful Management of a Patient with Multiple Nucleos(t)ide Analogue-Resistant Hepatitis B Virus and Diffuse Large B Cell Lymphoma Using Tenofovir Disoproxil Fumarate: A Case Report. <i>Journal of the Nihon University Medical Association</i> , 2019, 78, 295-300.	0.0	0
252	Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan. <i>In Vivo</i> , 2020, 34, 3309-3313.	0.6	0

#	ARTICLE	IF	CITATIONS
253	A Case of Recent Liver Injury Induced by Benzbromarone. Reports, 2022, 5, 8.	0.2	0